Differentiation of Hemorrhage from Iodine Using Spectral Detector CT: A Phantom Study

S. Van Hedent, N. Große Hokamp, K.R. Laukamp, N. Buls, R. Kessner, B. Rose, P. Ros, and D. Jordan

BACKGROUND AND PURPOSE: Conventional CT often cannot distinguish hemorrhage from iodine extravasation following reperfusion therapy for acute ischemic stroke. We investigated the potential of spectral detector CT in differentiating these lesions.

MATERIALS AND METHODS: Centrifuged blood with increasing hematocrit (5%–85%) was used to model hemorrhage. Pure blood, blood-iodine mixtures (75/25, 50/50, and 25/75 ratios), and iodine solutions (0–14 mg I/mL) were scanned in a phantom with attenuation ranging from 12 to 75 HU on conventional imaging. Conventional and virtual noncontrast attenuation was compared and investigated for correlation with calculation of relative virtual noncontrast attenuation. Values for all investigated categories were compared using the Mann-Whitney U test. Sensitivity and specificity of virtual noncontrast, relative virtual noncontrast, conventional CT attenuation, and iodine quantification for hemorrhage detection were determined with receiver operating characteristic analysis.

RESULTS: Conventional image attenuation was not significantly different among all samples containing blood (P > .05), while virtual noncontrast attenuation showed a significant decrease with a decreasing blood component (P < .01) in all blood-iodine mixtures. Relative virtual noncontrast values were significantly different among all investigated categories (P < .01), with correct hemorrhagic component size estimation for all categories within a 95% confidence interval. Areas under the curve for hemorrhage detection were 0.97, 0.87, 0.29, and 0.16 for virtual noncontrast, relative virtual noncontrast, conventional CT attenuation, and iodine quantification, respectively. A ≥10-HU virtual noncontrast, ≥20-HU virtual noncontrast, ≥40% relative virtual noncontrast, and combined ≥10-HU virtual noncontrast and ≥40% relative virtual noncontrast attenuation threshold had a sensitivity/specificity for detecting hemorrhage of 100%/23%, 89%/95%, 100%/82%, and 100%/100%, respectively.

CONCLUSIONS: Spectral detector CT can accurately differentiate blood from iodinated contrast in a phantom setting.

ABBREVIATIONS: ICH = intracranial hemorrhage; R-VNC = relative virtual noncontrast; SDCT = spectral detector CT; VNC = virtual noncontrast

Material with similar attenuation can be difficult to distinguish on conventional CT. A common clinical illustration of this problem is the differentiation of iodine from hemorrhage because both are hyperdense on conventional unenhanced CT. In patients with acute ischemic stroke, intra-arterial thrombolytic therapy has been shown to decrease morbidity and mortality. However, it has also been reported that this increases the risk of intracranial hemorrhage (ICH), with reported frequencies of 10%–15% and mortality up to 83% for symptomatic ICH. Because of the disruption of the blood-brain barrier, contrast extravasation can occur during the procedure in 30%–50% of cases, impairing the detection of or the differentiation from ICH due to the overlap in density. As of this writing, unenhanced conventional CT is performed within 24 hours after treatment for the detection of complications. In case of unclear findings (eg, if differentiation between ICH and iodine extravasation is not possible), follow-up imaging may be performed. Hence, the ability to differentiate these 2 is highly desirable to avoid additional examinations and to ensure appropriate management.

Received June 3, 2018; accepted after revision August 28.

From the Departments of Radiology (S.V.H., N.G.H., K.R.L., R.K., P.R., D.J.) and Pathology (B.R.), University Hospitals Cleveland Medical Center, Cleveland, Ohio; Case Western Reserve University School of Medicine (S.V.H., N.G.H., K.R.L., R.K., B.R., P.R., D.J.); Cleveland, Ohio; Institute for Diagnostic and Interventional Radiology (N.G.H., K.R.L.), University Hospital Cologne, Cologne, Germany; Vrije Universiteit Brussel (S.V.H., N.B.); Brussels, Belgium; and Department of Radiology (S.V.H., N.B.), Universitair Ziekenhuis Brussel, Brussels, Belgium.

Preliminary results previously presented as an electronic poster at: Annual Meeting of the European Congress of Radiology, February 28 to March 4, 2018; Vienna, Austria.

This work was partially supported by Philips Healthcare under a research agreement with University Hospitals Cleveland Medical Center and Case Western Reserve University.

Please address correspondence to Steven Van Hedent, Universitair Ziekenhuis Brussel, Department of Radiology, Laarbeeklaan 101, 1020 Brussels, Belgium; e-mail: steven.vanhedent@case.edu

http://dx.doi.org/10.3174/ajnr.A5872

AJNR Am J Neuroradiol 39:2205–10 Dec 2018 www.ajnr.org 2205
In our study, we investigated the ability of SDCT to differentiate ICH from iodinated contrast in a phantom model.

In our study, we investigated the ability of SDCT to differentiate iodine from hemorrhage in clinical settings. However, no study has been performed using SDCT for this application nor has the sensitivity or specificity been determined in a phantom system.

Two major discriminators of attenuation within a voxel are the energy of the x-ray beam and the concentration of attenuating material in that voxel. The presence or concentration of each discriminator in that voxel therefore cannot be determined by performing a single attenuation measurement from a broad photon energy spectrum. However, in dual-energy CT, attenuation at different energies is registered. In single- and dual-source dual-energy CT, this is achieved using a fast-kilovolt peak switching x-ray source (GE Healthcare, Milwaukee, Wisconsin) or 2 x-ray sources and 2 detectors (Somatom Force, Siemens Healthineers, Forchheim, Germany), respectively. Spectral detector CT (SDCT) (IQon; Philips Healthcare, Best, the Netherlands) distinguishes low- and high-energy data at the level of the detector using a dual-layer detector. The bottom and top layer absorb high- and low-energy photons, respectively. The main advantage of the latter approach is that spectral data are collected without the need to prospectively choose a spectral scanning protocol or mode, as needed in other dual-energy CT approaches.

Previous studies have shown the potential of dual-energy CT for differentiating iodine from hemorrhage in clinical settings; however, no study has been performed using SDCT for this application nor has the sensitivity or specificity been determined in a phantom system.

In our study, we investigated the ability of SDCT to differentiate ICH from iodinated contrast in a phantom model.

**MATERIALS AND METHODS**

**Image Acquisition**

All scans were performed with a 464 Phantom (Gammax, Madison, Wisconsin) with a plastic 50-mL tube in its air cavity, filled with samples simulating hemorrhage (blood), diluted iodine, and a hemorrhage-iodine (blood-iodine) mixture. Each sample was scanned in the phantom with the following settings on the IQon SDCT scanner: 200 mAs, 120 kVp, pitch = 1, gantry rotation time = 330 ms, detector collimation = 64 × 0.625 mm, volume CT dose index = 18 mGy. Conventional CT images were reconstructed using an iterative reconstruction algorithm (iDose 4, Level 3; Philips Healthcare), while the spectral images were reconstructed using a spectral reconstruction algorithm (Spectral B, level 0). Reconstructed slice thickness was 3 mm. All scans were performed 3 times to account for interscan variability.

**Sample Preparation**

Previous studies have shown that the density of blood is primarily determined by the hemoglobin concentration. In turn, changes in hematocrit are reflected in the density of a hemorrhage seen on conventional CT. We collected discarded packed red blood cells and prepared samples to a range of 0%, 5%, 15%, 25%, 35%, 45%, 55%, 65%, 75%, and 85% hematocrit. The packed red blood cells were prepared using phosphate buffered saline to prevent coagulation. Each sample was scanned with the protocol described above. Diluted iodine (Optiray 350, Ioviresol; Mallinckrodt, St. Louis, Missouri) samples in phosphate buffered saline, with concentrations ranging from 0 to 14 mg I/mL (0.00, 0.70, 1.40, 2.10, 2.80, 3.50, 4.20, 4.90, 5.60, 7.00, 14.00 mg I/mL) were scanned using the same protocol. We matched the iodine attenuation with the densities found for 85%, 75%, 65%, 55%, 45%, and 35% hematocrit to create iodine dilutions with matching densities (2.50, 2.10, 1.80, 1.40, 1.10, and 0.70 mg I/mL, respectively) at those hematocrit levels.

Blood-iodine mixtures with matching densities were scanned with following proportions: [2/3] blood + [1/3] iodine; [1/2] blood + [1/2] iodine; [1/3] blood + [2/3] iodine.

**Image Analysis**

All image analysis was performed using the proprietary image viewer (Spectral Diagnostic Suite; Philips Healthcare) of the vendor. Each diluted blood, diluted iodine, and blood-iodine mixture sample was analyzed by placing a circular 2-cm² ROI centrally in the inserts. The attenuation on the conventional and virtual noncontrast (VNC) image (using VNC image) and iodine concentration (using the iodine density map) were measured within each ROI (Fig 1). Relative VNC (R-VNC) attenuation (%) is calculated using the following equation:

$$R-VNC = \frac{\text{Attenuation VNC}}{\text{Attenuation Conventional}} \times 100.$$
ficity in detecting a hemorrhagic component. Receiver operating characteristic analysis was performed for conventional CT, VNC, R-VNC attenuation, and iodine quantification, and the corresponding areas under the curve with 95% CIs are reported. The difference among areas under the curve was assessed by the method of Hanley and McNeil. A P value < .05 was considered statistically significant.

**RESULTS**

Mean attenuation on the conventional and VNC images (± 95% CI) for the pure blood samples was similar: respectively, 39.1 ± 31.5–46.7 HU and 39.1 ± 31.5–46.7 HU (Fig 2 and the Table). The blood-iodine mixtures, consisting of [2 ⁄ 3] blood + [1 ⁄ 3] iodine; [1 ⁄ 2] blood + [1 ⁄ 2] iodine; [1 ⁄ 3] blood + [2 ⁄ 3] iodine had almost identical attenuation values on conventional images: 49.4 ± 42.8–56.2 HU, 49.2 ± 41.7–56.7 HU, and 49.4 ± 42.2–56.6 HU, respectively. Meanwhile, the corresponding VNC attenuation values incrementally decreased with an increasing iodine fraction, measuring 40.4 ± 35.9–44.9 HU, 32.6 ± 28.6–36.6 HU, and 26.0 ± 23.3–28.6 HU, respectively.

Differences in attenuation on the conventional images among the different investigated compositions containing a blood component were not significant (P > .05). Conversely, VNC attenuation values were significantly different among samples containing 67% blood, 50% blood, and 33% blood, but not among samples consisting of 100% and 67% blood (P = .70).

Conventional and VNC attenuation correlated significantly for all samples containing a blood component (R² > 0.97, P < .01). Correlation was highest for pure blood dilutions (R² = 1.00), followed by [2 ⁄ 3] blood + [1 ⁄ 3] iodine, [1 ⁄ 2] blood + [1 ⁄ 2] iodine mixtures, and it was lowest for samples containing [1 ⁄ 3] blood + [2 ⁄ 3] iodine (R² = 0.97).

Correlation between the hematocrit level in our samples and VNC attenuation was excellent (R² = 0.97, P < .01), while correlation with the attenuation on the conventional images was moderate, but still significant (R² = 0.50, P < .01) (Fig 3).

For the samples consisting only of diluted iodine, mean attenuation on conventional and VNC images (± 95% CI) was 129.5 ± 99.4–159.6 HU and 14.5 ± 13.4–15.6 HU, respectively, which were both significantly different from other samples containing a blood component (P < .01) (Fig 2 and the Table). When one interprets these results, it is important to note that phosphate buffered saline has different attenuation properties from normal saline. The average attenuation of samples filled with only phosphate buffered saline was 8.5 and 8.3 HU on conventional and VNC images, respectively. Correlation between conventional and VNC attenuation for samples with pure iodine dilutions was not significant (R² = 0.77, P = .08).

The differences between R-VNC attenuation values of all compositions were significant (P < .01), as shown in Fig 4 and the Table. Mean R-VNC attenuation (± 95% CI) for the pure blood, [2 ⁄ 3] blood – [1 ⁄ 3] iodine, [1 ⁄ 2] blood – [1 ⁄ 2] iodine, [1 ⁄ 3] blood – [2 ⁄ 3] iodine, and pure iodine was 99.59% ± 98.8%–100.4%, 82.8% ± 79.5%–86.1%, 67.6% ± 64.4%–70.9%, 54.3% ± 50.6%–58.0%, and 15.7% ± 12.4%–19.1%. There was no overlap within the 95% CI between R-VNC values for all compositions, contrary to VNC values in which all samples containing blood showed overlap.

There was a significant correlation between measured and true iodine concentrations (R² > 0.99, P < .01), with a mean iodine quantification error of ± 0.41 ± 0.31–0.50 mg/mL (Fig 5).

Receiver operating characteristic curve analysis for hemorrhagic-component detection showed a significant difference among areas under the curve (P < .01), being highest for VNC attenuation (0.97 ± 0.94–0.99 HU), followed by R-VNC attenuation (0.87 ± 0.77–0.97 HU) and attenuation in the conventional CT images (0.29 ± 0.16–0.41 HU), and lowest for iodine quantification (0.16 ± 0.06–0.25 HU) (Fig 6A); these differences were significant (P < .01). Using a threshold of ≥10 and ≥20 HU for VNC had a sensitivity/specificity of 100%/23% and 89%/95%, respectively. An R-VNC attenuation of ≥40% had a sensitivity/specificity of 100%/82%. Conversely, using a threshold of ≥10 and ≥20 HU on the conventional CT images had a sensitivity/specificity of 100%/13% and 94%/15%, respectively (Fig 6).

### Table: Attenuation values (HU) of diluted blood, blood-iodine mixtures, and diluted iodine on SDCT conventional and VNC images

| Composition                  | Conventional (HU) | Mean (95% CI)   | VNC (HU)       | Mean (95% CI)   | R-VNC (%) | Mean (95% CI)   |
|------------------------------|-------------------|-----------------|----------------|-----------------|-----------|-----------------|
| 100% blood–0% iodine         | 39.1              | 31.5–46.7       | 39.1           | 31.5–46.7       | 100%      | 99.8–100.4      |
| 67% blood–33% iodine         | 49.5              | 42.8–56.2       | 40.4           | 35.9–44.9       | 99.6      | 79.5–86.1       |
| 50% blood–50% iodine         | 49.2              | 41.7–56.7       | 32.6           | 28.6–36.6       | 82.8      | 64.4–70.9       |
| 33% blood–67% iodine         | 49.4              | 42.2–56.6       | 26.0           | 23.3–28.6       | 67.6      | 50.6–58.0       |
| 0% blood–100% iodine         | 129.5             | 99.4–159.6      | 14.5           | 13.4–15.6       | 15.7      | 12.4–19.1       |

*R-VNC attenuation (%) was calculated by comparing VNC attenuation with the attenuation on conventional CT for all investigated categories.*

**FIG. 2.** Attenuation values (HU) of diluted blood, blood-iodine mixtures, and diluted iodine on spectral detector CT conventional and virtual non-contrast images. There is a significant incremental decrease of VNC attenuation values with decreasing blood content. The asterisk indicates a significant difference of conventional CT attenuation compared with other compositions (P < .01); double asterisks, significant differences of VNC attenuation among these compositions (P < .01).
Our results show that SDCT has excellent diagnostic accuracy for differentiating blood from iodinated contrast in a phantom. We observed similar sensitivity and specificity (both >90%) for hemorrhage detection using spectral dual-layer VNC images, compared with previous clinical studies that used single- or dual-source dual-energy CT. These studies used visual assessment by radiologists for classifying hyperdensities on “simulated” conventional head CT images as hemorrhage or iodine; hyperdensities visible on VNC images were classified as having a hemorrhagic component. Although typical ICHs are hyperdense (>50 HU), they can be associated with a lower density due to anticoagulation, the presence of CSF with arachnoid laceration, or severe anemia (eg, sickle cell anemia), which can complicate subjective assessment. Our results show high accuracy by quantitative VNC assessment for blood detection, including low densities on conventional images (as low as 10 HU). By combining a ≥10 HU VNC and ≥40% R-VNC cutoff, we observed a sensitivity and specificity of 100% for blood, including low densities and mixtures with iodine on conventional images (Fig 6).

Several authors have investigated the accuracy of SDCT for material decomposition, which allows iodine to be subtracted from an image. These studies have shown high accuracy for iodine-quantification and VNC attenuation values, though results vary. Our results show slightly lower iodine-quantification accuracy than recent publications, which can be explained by the extremely low iodine concentrations needed in our study, though results are still excellent. We had results comparable with those of Pelgrim et al, which showed a median error of ~0.6 mg/mL, while more recent studies showed differences ranging from ~0.46 to 0.1 mg/mL. Regarding VNC, Duan et al showed good agreement between measured spectral detector VNC attenuation values and reference standards (~9.95–6.41 HU), confirmed by our study. Still, VNC inaccuracies can occur. When we incorporated a comparison of the attenuation between VNC and conventional images, small inaccuracies of true VNC values can be negated, which can explain the excellent results of R-VNC in our study for hemorrhage detection (100% sensitivity and 82% specificity) and size estimation (Figs 4 and 5).

Clinical studies using SDCT differentiating iodine from blood in skull imaging have been rare. As of this writing, the authors found only a pilot study from Cho et al, showing that spectral data analysis can be helpful in discriminating ICH from contrast enhancement in intracranial malignancies. Regarding the detection of hemorrhage, a recent study of Nute et al used single-source dual-energy CT for distinguishing ICH from calcification in a phantom model with densities from 40 to 100 HU, resulting in an accuracy of >90%.

There are several limitations to our study. First, our results are without clinical data because this was not within the scope of our investigation. Our goal was to investigate in a phantom setting. Second, our hemorrhage dilutions were prepared with phosphate buffered saline to prevent red blood cell hemolysis, but this could potentially bias the attenuation characteristics of blood and iodine in our results: Phosphate buffered saline is not representative of brain tissue in a clinical setting. Third, our mixtures were homogeneously mixed for optimal spectral analysis, which may not always be the case in a clinical setting. Last, we used a relatively large 2-cm² ROI for our measurements, so our results could not be affected by spatial resolution and partial volume limitations. This might not always be feasible in patients if the size of the clinical ROI is small.
CONCLUSIONS

Our results show that the added spectral information of SDCT has high sensitivity and specificity in detecting blood and can accurately estimate hemorrhagic component size, including when mixed with iodine. This information could be of potential benefit in brain imaging for patients following reperfusion therapy in acute stroke.

Disclosures: Steven Van Hedent—RELATED: Grant: Philips Healthcare, Comments: Partial funding support was provided by Philips Healthcare under a research agreement with University Hospitals Cleveland Medical Center and Case Western Reserve University.* Nils Grosse Hokamp—RELATED: Grant: University Hospitals Cleveland Medical Center/Case Western Reserve University/Philips Healthcare, Comments: Part of this Research was funded under a research agreement among University Hospitals Cleveland Medical Center, Case Western Reserve University, and Philips Healthcare*.

REFERENCES

1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–87 CrossRef Medline
2. Mokin M, Kan P, Kass-Hout T, et al. Intracerebral hemorrhage secondary to intravenous and endovascular intraarterial recanalization therapies in acute ischemic stroke: an update on risk factors, predictors, and management. Neurosurg Focus 2012;32:E2 CrossRef Medline
3. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European
Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999;30:2280–84 CrossRef Medline
4. Nakano S, Iseda T, Kawano H, et al. Parenchymal hyperdensity on computed tomography after intra-arterial reperfusion therapy for acute middle cerebral artery occlusion: incidence and clinical significance. Stroke 2001;32:2042–48 CrossRef Medline
5. Yoon W, Seo JJ, Kim JK, et al. Contrast enhancement and contrast extravasation on computed tomography after intra-arterial thrombolyis in patients with acute ischemic stroke. Stroke 2004;35:876–81 CrossRef Medline
6. Yedavalli V, Sammet S. Contrast extravasation versus hemorrhage after thrombectomy in patients with acute stroke. J Neuroimaging 2017;27:570–76 CrossRef Medline
7. Greer DM, Korshetz WJ, Callen S, et al. Magnetic resonance imaging improves detection of intracerebral hemorrhage over computed tomography after intra-arterial thrombolysis. Stroke 2004;35:491–95 CrossRef Medline
8. Jang YM, Lee DH, Kim HS, et al. The fate of high-density lesions on the non-contrast CT obtained immediately after intra-arterial thrombolyis in ischemic stroke patients. Korean J Radiol 2006;7:221–28 CrossRef Medline
9. Mericle RA, Lopes DK, Gronckowiak MD, et al. A grading scale to predict outcomes after intra-arterial thrombolysis for stroke complicated by contrast extravasation. Neurosurgery 2000;46:1307–14; discussion 14–15 CrossRef Medline
10. Gupta R, Phan CM, Leidecker C, et al. Evaluation of dual-energy CT for differentiating intracerebral hemorrhage from iodinated contrast material staining. Radiology 2010;257:205–11 CrossRef Medline
11. Yokogami K, Nakano S, Ohta H, et al. Prediction of hemorrhagic complications after thrombolytic therapy for middle cerebral artery occlusion: value of pre- and post-therapeutic computed tomographic findings and angiographic occlusive site. Neurosurgery 1996;39:1102–07 CrossRef Medline
12. Siddiqui FM, Bekker SV, Qureshi AI. Neuroimaging of hemorrhage and vascular defects. Neurotherapeutics 2011;8:28–38 CrossRef Medline
13. Tijssen MP, Hofman PA, Stadler AA, et al. The role of dual energy CT in differentiating between brain haemorrhage and contrast medium after mechanical revascularisation in acute ischaemic stroke. Eur Radiol 2014;24:834–40 CrossRef Medline
14. Nute JL, Le Roux L, Chandler AG, et al. Differentiation of low-attenuation intracranial hemorrhage and calcification using dual-energy computed tomography in a phantom system. Invest Radiol 2015;50:9–16 CrossRef Medline
15. Phan CM, Yoo AJ, Hirsch JA, et al. Differentiation of hemorrhage from iodinated contrast in different intracranial compartments using dual-energy head CT. AJNR Am J Neuroradiol 2012;33:1088–94 CrossRef Medline
16. Hu R, Padole A, Gupta R. Dual-energy computed tomographic applications for differentiation of intracranial hemorrhage, calcium, and iodine. Neuroimaging Clin N Am 2017;27:401–09 CrossRef Medline
17. New PF, Aronow S. Attenuation measurements of whole blood and blood fractions in computed tomography. Radiology 1976;121(3 Pt. 1):635–40 CrossRef Medline
18. Bergström M, Ericson K, Levander B, et al. Variation with time of the attenuation values of intracranial hematomas. J Comput Assist Tomogr 1977;1:57–63 CrossRef Medline
19. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36 CrossRef Medline
20. Grelat M, Madkouri R, Bousquet O. Acute isodense subdural hematoma on computed tomography scan—diagnostic and therapeutic trap: a case report. J Med Case Rep 2016;10:43 CrossRef Medline
21. Lee KS, Bae WK, Bae HG, et al. The computed tomographic attenuation and the age of subdural hematomas. J Korean Med Sci 1997;12:353–59 CrossRef Medline
22. Boyko OB, Cooper DF, Grossman CB. Contrast-enhanced CT of acute isodense subdural hematoma. AJNR Am J Neuroradiol 1991;12:341–43 Medline
23. Mendonca R, Lima TT, Dini LI, et al. Bilateral isodense epidural hematoma: case report. Arq Neuropsiquiatr 2005;63:862–63 CrossRef Medline
24. May PL, Miles JB. Acute isodense extradural haematoma. Br J Neurosurg 1989;3:221–24 CrossRef Medline
25. Rieth KG, Schwartz FT, Davis DO. Acute isodense epidural hematoma on computed tomography. J Comput Assist Tomogr 1979;3:691–93 CrossRef Medline
26. Harbury OL, Provenzale JM, Barbiorak DP. Vertex epidural hematomas: imaging findings and diagnostic pitfalls. Eur J Radiol 2000;36:150–57 CrossRef Medline
27. Claes F, Verhagen CV, Verhagen WI, et al. Acute isodense intracerebral haematoma due to coagulopathy associated with prostate cancer. Clin Neurol Neurosurg 2007;109:520–22 CrossRef Medline
28. Kaufman HH, Singer JM, Sadhu VK, et al. Isodense acute subdural hematoma. J Comput Assist Tomogr 1980;4:557–59 CrossRef Medline
29. Thust SC, Burke C, Siddiqui A. Neuroimaging findings in sickle cell disease. Br J Radiol 2014;87:20130699 CrossRef Medline
30. Pelgrin GI, van Hamersvelt RW, Willemsen MJ, et al. Accuracy of iodine quantification using dual energy CT in latest generation dual source and dual layer CT. Eur Radiol 2017;27:3904–12 CrossRef Medline
31. Duan X, Arbieque G, Guild J, et al. Technical note: quantitative accuracy evaluation for spectral images from a detector-based spectral CT scanner using an iodine phantom. Med Phys 2018;45:2048–53 CrossRef Medline
32. Cho SB, Baek HJ, Ryu KH, et al. Initial clinical experience with dual-layer detector spectral CT in patients with acute intracerebral haemorrhage: a single-centre pilot study. PLoS One 2017;12:e0186024 CrossRef Medline
33. Nute JL, Jacobsen MC, Chandler A, et al. Dual-energy computed tomography for the characterization of intracranial hemorrhage and calcification: a systematic approach in a phantom system. Invest Radiol 2017;52:30–41 CrossRef Medline